Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Head & Neck 1

Conditions

Stomatitis 2Mucositis 2Pain, Postoperative 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Anastomotic Leak 1

Interventions

Cisplatin 131Cetuximab 80Radiotherapy 76Docetaxel 59Carboplatin 46pembrolizumab 45Paclitaxel 44Fluorouracil 42Radiotherapy, Intensity-Modulated 35Drug Therapy 17Radiation 14Nivolumab 14Gefitinib 14Gemcitabine 13Surgical Procedures, Operative 12Oxaliplatin 11Erlotinib Hydrochloride 11130-nm albumin-bound paclitaxel 11Pemetrexed 10Celecoxib 10Capecitabine 10Bevacizumab 10tislelizumab 9Filgrastim 9Amifostine 9Albumin-Bound Paclitaxel 9durvalumab 7atezolizumab 7Chemoradiotherapy 7toripalimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Head and Neck Neoplasms × Water × Clear all
NCT02324335 2019-01-16

Brilacidin

Innovation Pharmaceuticals, Inc.

Phase 2 Completed
61 enrolled 12 charts
Head & NeckOther

Head and Neck Neoplasms, Stomatitis, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡